262 related articles for article (PubMed ID: 37993280)
21. Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells.
Mise N; Takami M; Suzuki A; Kamata T; Harada K; Hishiki T; Saito T; Terui K; Mitsunaga T; Nakata M; Ikeuchi T; Nakayama T; Yoshida H; Motohashi S
Cancer Sci; 2016 Mar; 107(3):233-41. PubMed ID: 26749374
[TBL] [Abstract][Full Text] [Related]
22. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
23. Immune contexture of paediatric cancers.
Thakur MD; Franz CJ; Brennan L; Brouwer-Visser J; Tam R; Korski K; Koeppen H; Ziai J; Babitzki G; Ranchere-Vince D; Vasiljevic A; Dijoud F; Marec-Bérard P; Rochet I; Cannarile MA; Marabelle A
Eur J Cancer; 2022 Jul; 170():179-193. PubMed ID: 35660252
[TBL] [Abstract][Full Text] [Related]
24. Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model.
van den Bijgaart RJE; Kroesen M; Brok IC; Reijnen D; Wassink M; Boon L; Hoogerbrugge PM; Adema GJ
Oncoimmunology; 2020 Sep; 9(1):1817653. PubMed ID: 33457098
[TBL] [Abstract][Full Text] [Related]
25. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
26. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
Tanaka M; Tashiro H; Omer B; Lapteva N; Ando J; Ngo M; Mehta B; Dotti G; Kinchington PR; Leen AM; Rossig C; Rooney CM
Clin Cancer Res; 2017 Jul; 23(14):3499-3509. PubMed ID: 28183713
[No Abstract] [Full Text] [Related]
27. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.
Bocca P; Di Carlo E; Caruana I; Emionite L; Cilli M; De Angelis B; Quintarelli C; Pezzolo A; Raffaghello L; Morandi F; Locatelli F; Pistoia V; Prigione I
Oncoimmunology; 2017; 7(1):e1378843. PubMed ID: 29296542
[TBL] [Abstract][Full Text] [Related]
29. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
[TBL] [Abstract][Full Text] [Related]
30. Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model.
Ivasko SM; Anders K; Grunewald L; Launspach M; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Lode HN; Andersch L; Schulte JH; Eggert A; Hundsdoerfer P; Künkele A; Zirngibl F
Front Immunol; 2022; 13():1023206. PubMed ID: 36700232
[TBL] [Abstract][Full Text] [Related]
31. Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells.
McNerney KO; Karageorgos SA; Hogarty MD; Bassiri H
Front Immunol; 2020; 11():873. PubMed ID: 32457760
[TBL] [Abstract][Full Text] [Related]
32. Monocyte and Macrophage in Neuroblastoma: Blocking Their Pro-Tumoral Functions and Strengthening Their Crosstalk with Natural Killer Cells.
Vitale C; Bottino C; Castriconi R
Cells; 2023 Mar; 12(6):. PubMed ID: 36980226
[TBL] [Abstract][Full Text] [Related]
33. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
Voeller J; Sondel PM
J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608
[TBL] [Abstract][Full Text] [Related]
34. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Heczey A; Courtney AN; Montalbano A; Robinson S; Liu K; Li M; Ghatwai N; Dakhova O; Liu B; Raveh-Sadka T; Chauvin-Fleurence CN; Xu X; Ngai H; Di Pierro EJ; Savoldo B; Dotti G; Metelitsa LS
Nat Med; 2020 Nov; 26(11):1686-1690. PubMed ID: 33046868
[TBL] [Abstract][Full Text] [Related]
35. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
36. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
[TBL] [Abstract][Full Text] [Related]
37. Biological Insight and Recent Advancement in the Treatment of Neuroblastoma.
Rivera Z; Escutia C; Madonna MB; Gupta KH
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239815
[TBL] [Abstract][Full Text] [Related]
38. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484
[TBL] [Abstract][Full Text] [Related]
39. Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer.
Iyoda T; Yamasaki S; Ueda S; Shimizu K; Fujii SI
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830717
[TBL] [Abstract][Full Text] [Related]
40. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
Singh N; Liu X; Hulitt J; Jiang S; June CH; Grupp SA; Barrett DM; Zhao Y
Cancer Immunol Res; 2014 Nov; 2(11):1059-70. PubMed ID: 25104548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]